Svetlana Lucas has bought stock on 2 days since Sep 2025
Chief Business Officer at Scribe Therapeutics Inc., and 1 other company
SEC CIK 0001781292 · Filings on SEC.gov ↗
Svetlana Lucas's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
2 filings since Sep 2025, newest first
About Svetlana Lucas
Svetlana Lucas, Ph.D. is an independent Class III Director at Jasper Therapeutics, Inc. (NASDAQ: JSPR), serving since June 2024, and a member of the Nominating & Corporate Governance Committee.( With over 20 years of experience in strategy, business development, and commercialization in immunology and oncology, she recently purchased 20,000 shares of JSPR common stock at $2.43 per share (totaling $48,600) and 20,000 common stock warrants on September 22, 2025.(
Dr. Lucas earned her Ph.D. in Molecular Biology & Biochemistry from the California Institute of Technology (Caltech) and an undergraduate degree in Biology from Moscow State University.( Her career highlights include serving as Chief Business Officer at Scribe Therapeutics since June 2019, where she led strategic collaborations with Sanofi and Eli Lilly’s Prevail Therapeutics; Senior Vice President of Business Development at Tizona Therapeutics, driving a global deal with AbbVie; Head of Oncology & Inflammation External R&D at Amgen, overseeing the Kite Pharma collaboration; and roles at Onyx Pharmaceuticals, PDL BioPharma/Facet Biotech, XOMA, and McKinsey & Company.( She currently serves on the Board of Directors at aTyr Pharma, Inc. (NASDAQ: ATYR) since June 2019 and as an Advisor to Radar Therapeutics since October 2023.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.